Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544718 | 1.00 | DPP4 (0.40) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL20545344 | 0.89 | DPP4 (0.43) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL20545347 | 0.89 | DPP4 (0.43) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL20838281 | 0.86 | CYP2D6 (0.41) | DPP4POLBNR1I2SMN1; SMN2LMNA | |
| SCHEMBL18850971 | 0.86 | F2 (0.38) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL7131093 | 0.79 | EPHX1 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6828378 | 0.79 | EPHX1 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5216741 | 0.78 | HTT (0.49) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL3276055 | 0.78 | POLB (0.40) | DPP4POLBSPHK1HTTNR1I2 | |
| SCHEMBL3740451 | 0.78 | HTT (0.49) | DPP4POLBSPHK1HTTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | UGT1A8, CYP2C8, CXCL8 | DPP4 1498/4885POLB 2549/4885SPHK1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.